Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

Julien Hadoux, Christina Kanaan, Alice Durand, S. Hescot, Vincent Hautefeuille, Guillaume Cadiot, Igor Tauveron, Sandrine Laboureau, Christine Do Cao, Thomas Walter, Caroline Pétorin, Odile Blanchet, Arnaud Jannin, Céline Gu, Matthieu Faron, Emmanuelle Leteurtre, Marie‐Christine Rousselet, Juliette Joubert Zakeyh, Aude Marchal, Denis Chatelain, Clément Beaulaton, Valérie Hervieu, Michel Ducreux, Jean‐Yves Scoazec, Éric Baudin